drugset / Trial / NCT06727409
Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
NaSingle-groupOpen-labelTreatment
Summary
To evaluate triple therapy with nsMRA, RASi and SGLT2i on albuminuria in individuals with T2D and CKD
Timeline
- Start
- 2024-12-12
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finerenone | Small molecule | 10 mg | — |
| Subject | Finerenone | Small molecule | 20 mg | — |
Indications
No indication recorded.